Results 201 to 210 of about 93,850 (311)
Tax Evasion and Business Ethics: A Comparative Study of Guatemala and the USA
Robert W. McGee, Christopher Lingle
openalex +1 more source
DDR1 drives cervical cancer progression and immune evasion: a bioinformatics analysis with experimental verification. [PDF]
Zhou Y, Guo X, Han J, Ding W.
europepmc +1 more source
Expanding enzalutamide (ENZ) use in hormone‐sensitive prostate cancer (HSPC) faces resistance. Single‐cell profiling identifies therapy‐resistant STEAP4+ myofibroblastic cancer‐associated fibroblast (SETAP4+ myoCAF). These myoCAFs drive resistance via TFE3‐mediated autophagy and PCYT1A‐led phosphatidylcholine overproduction, creating a phospholipid ...
Wenhao Wang +14 more
wiley +1 more source
AI-based non-invasive profiling of the tumor immune microenvironment using longitudinal CT radiomics predicts immunotherapy response in lung cancer. [PDF]
Liu G +10 more
europepmc +1 more source
This study presents the sono‐sensitive nanorobot Sono@NAT10, which targets NAT10 condensates to reprogram tumor‐associated macrophages in colorectal cancer. By reducing the acetylation level of SRSF2 protein and activating HDAC10, Sono@NAT10 promotes M1 polarization, suppresses tumor progression, and strengthens immunotherapy. The approach demonstrates
Jiahao Zhu +11 more
wiley +1 more source
Protein translation dysregulation and immune cell evasion mediated by IFN and immunoproteasome downregulation define metastatic clones in HPV-related cancer of the oropharynx. [PDF]
Chin VT +15 more
europepmc +1 more source
High PIVKA‐II expression in HCC correlates with resistance to anti‐PD‐1 plus lenvatinib, driven by an immunosuppressive TME. NQO1/p65/CXCL12 axis recruits Tregs to promote resistance to anti‐PD‐1 plus lenvatinib in HCC with high PIVKA‐II expression.
Biao Gao +18 more
wiley +1 more source
The Ethics of Tax Evasion: An Empirical Study of Ecuador
Robert W. McGee +2 more
openalex +1 more source
MiR-518c-5p/miR-4524a-3p can mediate immune escape and chemotherapy resistance in triple-negative breast cancer and predict its outcome. [PDF]
Sun Y +6 more
europepmc +1 more source
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source

